Irlandia - angielski - HPRA (Health Products Regulatory Authority)

amdipharm limited - levothyroxine sodium - tablet - 100 microgram(s) - thyroid hormones; levothyroxine sodium

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

amdipharm limited - levothyroxine sodium - tablet - 50 microgram(s) - thyroid hormones; levothyroxine sodium

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

amdipharm limited - tirofiban hydrochloride (unii: 6h925f8o5j) (tirofiban - unii:ggx234si5h) -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - erythromycin lactobionate, quantity: 1515 mg (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - indications as at 1 november 2002: oral erythromycin is not considered to be the antibiotic of choice in severely ill patients. erythrocin-i.v. (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time. upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae). respiratory tract infections due to mycoplasma pneumoniae. skin and skin structure infections caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment). diphtheria - as an adjunct to diphtheria antitoxin in infections due to corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers. acute pelvic inflammatory disease caused by neisseria gonorrhoeae: erythrocin-i.v. (sterile erythromycin lactobionate) followed by erythromycin stearate, base or ethyl succinate orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin. before treatment of gonorrhoea, patients who are suspected of also having syphilis should have microscopic examination for t. pallidum (by immunofluorescence or darkfield) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter. legionnaires' disease caused by legionella pneumophila. although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - auranofin, quantity: 3 mg - tablet, film coated - excipient ingredients: titanium dioxide; maize starch; lactose monohydrate; magnesium stearate; iron oxide yellow; microcrystalline cellulose; hypromellose; purified water; sodium starch glycollate; propylene glycol; ethanol - indications as at 14 november 2000: adjunctive treatment of active classical or definite rheumatoid arthritis in adults who have an insufficient therapeutic response to, or are intolerant of, an adequate trial of a baseline therapeutic program, including among other measures, full doses of one or more non-steroidal anti-inflammatory drugs. ridaura is not indicated in non-rheumatoid arthropathies such as osteoarthrosis. ridaura should be added to a comprehensive baseline therapeutic program.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - imipramine hydrochloride, quantity: 10 mg - tablet, sugar coated - excipient ingredients: macrogol 8000; povidone; stearic acid; hypromellose; purified talc; glycerol; magnesium stearate; titanium dioxide; maize starch; microcrystalline cellulose; iron oxide red; colloidal anhydrous silica; lactose monohydrate; sucrose; copovidone - major depression. nocturnal enuresis (from the age of 5 years onwards and provided the possibility of organic causes has first been excluded).

Australia - angielski - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - chlortalidone, quantity: 25 mg - tablet, uncoated - excipient ingredients: purified talc; iron oxide yellow; iron oxide red; colloidal anhydrous silica; lactose monohydrate; maize starch; magnesium stearate - indications as at 19 november 1996: essential arterial hypertension, as long as creatinine clearance is >30 ml/min; as primary therapy or in combination with other antihypertensive agents; stable, chronic heart failure of mild to moderate degree (functional class ii, iii), as long as creatinine clearance is >30ml/min; ascites due to cirrhosis of the liver in stable patients under close control.

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

amdipharm limited - erythromycin - film-coated tablet - 250 milligram(s) - macrolides; erythromycin

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

amdipharm limited - erythromycin - film-coated tablet - 500 milligram(s) - macrolides; erythromycin

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

amdipharm limited - erythromycin - granules for oral suspension - 500 mg/5ml - macrolides; erythromycin